Allogene Therapeutics (ALLO) Q1 2024 Earnings
ALLO·Reported May 13, 2024·After market close
Allogene Therapeutics reported Q1 2024 revenue of $22.0K, beat analyst consensus of $10.0K by $12.0K. Diluted EPS came in at $-0.38.
Revenue
$22.0Kbeat by $12.0K
Consensus: $10.0KDiluted EPS
$-0.38met estimate
Consensus: $-0.38
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Allogene Therapeutics's Q1 2024 earnings report.
Allogene Therapeutics (ALLO) reported Q1 2024 earnings on May 13, 2024 after market close.
Allogene Therapeutics reported revenue of $22.0K and diluted EPS of $-0.38 for Q1 2024.
Revenue beat the consensus estimate of $10.0K by $12.0K. EPS beat the consensus estimate of $-0.38 by $0.00.
You can read the 10-Q periodic report (0001737287-24-000041) directly on SEC EDGAR. The filing index links above go to sec.gov.